Topic:

Europe

Latest Headlines

Latest Headlines

BTG, Philips roll out first cancer embolic bead visible via real-time imaging

Until now, interventional radiologists and oncologists had no means to be certain that when embolic beads were placed into blood vessels at the precise, intended location or that they remained there over time. Now, partners BTG and Royal Philips have treated the first liver cancer patient with their recently approved LC Bead Lumi that is visible via imaging and can be used during an embolization procedure as well as afterward to monitor that the embolic beads remain in their intended location.

St. Jude launches portable, intravascular cardiac imaging system in Europe, Japan

St. Jude Medical has launched a portable version in Europe and Japan of its system to offer physicians a view from within the heart to enable physicians to make decisions during catheter-based stenting procedures. Dubbed Optis Mobile, the system is expected to offer comparable imaging as compared to the company's already marketed Optis Integrated System.

U.K.'s NHS commits $6B to digital health, making remote care a priority

The U.K.'s National Health Service hasn't exactly earned high marks so far for its efforts on the digital health front. Its prior efforts to convert to electronic medical records have failed. But the health program is redoubling its efforts now by committing £4.2 billion ($6 billion) to a variety of digital health initiatives. That news comes on the heels of the agency announcing a series of 7 med tech-focused trials with major technology partners including Alphabet's Verily, Royal Philips and Accenture.

Cellnovo partners with TypeZero in major NIH-backed artificial pancreas trial in Type 1 diabetics

Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.

U.K. public life science investment hits £1.3B; Mission bags £60M; Pierre Fabre starts VC fund

In this week's EuroBiotech Report, the London Stock Exchange said public life science investment hit a decade-long high in 2015. A bumper year for follow-on offerings drove the total investment up to £1.3 billion ($1.9 billion), a significant sum that masks the dearth of major IPOs. And more.

InflaRx starts preparation for PhIIb septic organ dysfunction trial after clearing safety study

InflaRx has posted positive safety data from a Phase IIa trial of its treatment for early septic organ dysfunction. Having met the primary endpoints in the study, InflaRx is now sifting through the data ahead of planned meetings with regulators to discuss the design of a Phase IIb trial.

Pierre Fabre starts open-ended collaborative translational R&D fund

Pierre Fabre has entered the world of biotech investing with a vehicle for equity funding and R&D co-financing deals. But, while an open-ended sum of cash is theoretically available, the French firm is placing as much emphasis on the support it can provide fledgling biotechs at a critical stage of drug development.

Mission set to push Parkinson's, cancer drugs into PhI after scooping £60M

Mission Therapeutics is gearing up to move drugs from its Parkinson's disease and immuno-oncology programs into the clinic. The activity is to be fuelled by a £60 million ($88 million) investment, which has given the company the financial firepower to take a pair of programs based on its DUB platform through to Phase I data readouts over the next three to four years.

U.K. keeps funding for clinical research sites flat through to 2022

The United Kingdom government is to pump £112 million ($160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment bolstering the attractiveness of the U.K. as a location for early-stage research, but the facilities will need to pull off these improvements without the benefit of access to a meaningfully bigger pot of money.

Follow-on bonanza drives U.K. investment in life science stocks past £1B

At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed to be 2015's Circassia, the big success story of 2014, leaving AIM listings and outliers such as PureTech as the most notable London IPOs of the year. And yet, from another angle, 2015 looks like a landmark year.
'